



**THE FOUNDATION
FOR SECURE
MARKETS®**

#53015

Date: August 11, 2023

Subject: Adjusted Sigilon Therapeutics, Inc. - Further Adjustment/Cash
Settlement/Acceleration of Expirations
Adjusted Option Symbol: SGTX1
Date: 08/11/2023

Adjusted Sigilon Therapeutics, Inc. (adjusted option symbol SGTX1) options were adjusted on May 23, 2023 (See OCC Information Memo #52595). The new deliverable for SGTX1 became 1) 7 Sigilon Therapeutics, Inc. (SGTX) Common Shares and 2) \$3.95 Cash.

On August 9, 2023, Cleopatra Acquisition Corp., Shenandoah Acquisition Corporation, a wholly owned subsidiary of Eli Lilly and Company, completed its tender offer for Sigilon Therapeutics, Inc. (SGTX). The subsequent merger was consummated before the open on August 11, 2023. As a result, each existing SGTX Common Share will be converted into the right to receive \$14.92 net cash per share plus one non-transferable contingent value right (CVR) for each share of Common stock of Sigilon Therapeutics, Inc.

NOTE: The CVR represents a non-transferable contractual right to receive an additional payment as described in the offer. SGTX1 options will not be adjusted to call for the delivery of the CVRs.

Adjusted SGTX1 options will be further adjusted as described below.

Contract Adjustment

Date: August 11, 2023

New Deliverable
Per Contract: \$108.39 Cash $((\$14.92 \times 7) + \$3.95)$

Settlement in SGTX1 options will take place through OCC's cash settlement system. Settlement will be accomplished by payment of the difference between the extended strike amount and the cash deliverable.

Acceleration of Expirations

Pursuant to OCC Rule 807, equity stock option contracts whose deliverables are adjusted to call for cash-only delivery will be subject to an acceleration of the expiration dates for outstanding option series. (See OCC Information Memo 23707) Additionally, the exercise by exception (ex by ex) threshold for expiring series will be \$.01 in all account types.

All series of Adjusted Sigilon Therapeutics, Inc. options whose expiration dates are after 08-18-2023 will have their expiration dates advanced to 08-18-2023. Expiration dates occurring before 08-18-2023 (e.g., Flex options) will remain unchanged.

All Adjusted Sigilon Therapeutics, Inc. options will utilize a \$.01 exercise threshold.

Option Symbol: SGTX1

Existing Expiration: All months

New expiration date: 08-18-2023

Existing American-style Adjusted Sigilon Therapeutics, Inc. options remain exercisable at the option of the holder prior to their expiration. Exercised options will continue to settle in two business days.

Disclaimer

This Information Memo provides an unofficial summary of the terms of corporate events affecting listed options or futures prepared for the convenience of market participants. OCC accepts no responsibility for the accuracy or completeness of the summary, particularly for information which may be relevant to investment decisions. Option or futures investors should independently ascertain and evaluate all information concerning this corporate event(s).

The determination to adjust options and the nature of any adjustment is made by OCC pursuant to OCC By-Laws, Article VI, Sections 11 and 11A. The determination to adjust futures and the nature of any adjustment is made by OCC pursuant to OCC By-Laws, Article XII, Sections 3, 4, or 4A, as applicable. For both options and futures, each adjustment decision is made on a case by case basis. Adjustment decisions are based on information available at the time and are subject to change as additional information becomes available or if there are material changes to the terms of the corporate event(s) occasioning the adjustment.

ALL CLEARING MEMBERS ARE REQUESTED TO IMMEDIATELY ADVISE ALL BRANCH OFFICES AND CORRESPONDENTS ON THE ABOVE.

For questions regarding this memo, please email the Investor Education team at options@theocc.com. Clearing Member Firms of OCC may contact Member Services at 1-800-544-6091 or, within Canada, at 1-800-424-7320, or email memberservices@theocc.com.